Loading
Cancer, Hypoxia, and Metabolism / Immune Cells in Cancer / Cancer Research and Treatments · Journal article
The Journal of Immunology · July 28, 2026
Encouraging direction, but not yet definitive.
This preclinical study shows that CRISPR knockout of MCT4 in MC38 syngeneic tumors reduces tumor growth and increases rejection in immunocompetent mice, with enhanced CD8 and CD4 T cell infiltration and higher survival when combined with mRNA vaccination. The effect was minimal in immunodeficient mice, suggesting immune dependence. CD8 T cells from MCT4-knockout tumors showed elevated spare respiratory capacity, indicating metabolic reprogramming.
Preclinical syngeneic tumor study with CRISPR genetic intervention. Mice (immunocompetent and immunodeficient strains) engrafted with MC38 wild-type or MCT4-knockout syngeneic tumors.. Intervention: MCT4 knockout in MC38 tumor cells (via CRISPR); therapeutic mRNA vaccination (neoAg-mRNA) in mice with well-engrafted MCT4-knockout tumors. Compared with: MC38 wild-type tumors; untreated or non-vaccinated controls.
MC38 Mct4-KO tumors showed reduced tumor growth and increased rejection rates in immunocompetent mice MCT4-knockout TME demonstrated increased CD8 and CD4 T cell infiltration with higher cytotoxic functionality Therapeutic mRNA vaccination in MC38 Mct4-KO tumor-bearing mice generated longer survival and more potent cytotoxic intratumoral immune response than MC38 tumor-bearing animals
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical finding suggests a potential strategy to enhance mRNA cancer vaccine efficacy by targeting tumor lactate metabolism. Clinical translation would require validation in additional models and human studies before informing patient treatment.
A mechanistic preclinical study in syngeneic mouse tumors demonstrating that MCT4 knockout enhances mRNA vaccine efficacy through immune microenvironment reprogramming, requiring confirmation in larger models and clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical finding suggests a potential strategy to enhance mRNA cancer vaccine efficacy by targeting tumor lactate metabolism. Clinical translation would require validation in additional models and human studies before informing patient treatment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Introduction We elucidated the impact of cancer metabolism components to potentiate the anti-tumoral effects of therapeutic mRNA vaccines. MCT4 facilitates the symport of lactate and protons to the extracellular environment contributing in the acidification of extracellular environment and consequently initiation of immune escape mechanisms by cancer cells and it is highly associated with poor cancer patient prognosis Methods CRISP knock out of MCT4 in MC38 cells; in vitro and ex vivo metabolic assays; tumor growth and survival in mice; mRNA-therapy; histology; flow cytometry; isotype tracing. Results In vivo studies using MC38 Mct-4 ko tumor cells showed reduced tumor growth and increased rejection rates in immunocompetent mice, while minimal differences in immunodeficient mice, suggesting a high immune response within the MC38 Mct4-KO’s tumor microenvironment (TME). We showed that MC38 Mct4-KO TME increased CD8 and CD4 T cell infiltration with higher cytotoxic functionality and a pro-inflammatory environment characterized by enriched nutrients availability, lower level of lactate and reduced hypoxic areas. Therapeutic mRNA vaccinations, conducted in mice with well-engrafted MC38 Mct4-KO tumors, generated a longer survival rate and a more potent cytotoxic intratumoral immune response then MC38 tumor bearing animals. Interestingly, Seahorse® analysis of tumor-infiltrating CD8 T cells from neoAg-mRNA vaccinated mice revealed that cytotoxic lymphocytes within the Mct4-KO TME displayed a modest increase in the maximal respiratory capacity and a significantly elevated spare respiratory capacity then lymphocyte isolated from MC38 tumors, indicating an enhancement of oxidative metabolic program and metabolic stress adaptions in Mct4-KO tumors with reduced lactate. Conclusion These findings provide valuable insights into optimizing mRNA vaccination by blocking the lactate transporter MCT4 in cancer cells for more efficient therapies for cancer patients. Funding Source n/a Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.